Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases.
Three patients of advanced-non-seminomatous germ cell tumors (International Germ Cell Cancer Collaborative Group classification: poor risk, 2; intermediate, 1) without evidence of a second primary germ cell tumor were treated. The patients received two cycles of standard BEP (bleomycin, etopside, cisplatin) or VIP/VB (etoposide, ifosphamide, cisplatin/vinblastine, bleomycin) therapy first. All patients in this trial showed unfavorable marker response to these therapies and received four cycles of TIP subsequently. A complete remission was observed in all patients. No patient experienced life-threatening toxicity. During the 34-month observation period, all patients were alive without progression.
Ishioka
Jun-Ichiro
J
Komuro, Ina, Kita adachi gun, Saitama, Japan. ishioka@jb3.so-net.ne.jp
Kageyama
Yukio
Y
Ichiyanagi
Nobutaka
N
Fukuda
Hiroshi
H
Higashi
Yotsuo
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy*
D014408:Biomarkers, Tumor; D017239:Paclitaxel; D002945:Cisplatin; D007069:Ifosfamide